Neoadjuvant and adjuvant therapies in prostate cancer.
Prostate cancer is the most common cancer in men in the United States and the second leading cause of cancer death. Advances in surgical therapies have paralleled advances in radiation therapy and chemotherapy for metastatic disease. There is a great interest in neoadjuvant and adjuvant therapies for patients at intermediate and high risk of recurrence and prostate cancer-specific death. Because high-risk prostate cancer patients can be readily identified by clinical criteria, many studies have attempted to use local and systemic adjuvant therapy to reduce the risk of recurrence. This review discusses neoadjuvant and adjuvant therapies in prostate cancer, including hormonal therapy, chemotherapy, and postoperative radiotherapy.
Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02215, USA.
Fabio A B
FA
Schutz
William K
WK
Oh
D017024:Chemotherapy, Adjuvant; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local; D011471:Prostatic Neoplasms / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D016896:Treatment Outcome